Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
McKinsey
Harvard Business School
Farmers Insurance
UBS
Fish and Richardson
US Department of Justice
McKesson
Moodys

Generated: September 20, 2018

DrugPatentWatch Database Preview

Ucb Inc Company Profile

« Back to Dashboard

What is the competitive landscape for UCB INC, and when can generic versions of UCB INC drugs launch?

UCB INC has thirty-nine approved drugs.

There are fifteen US patents protecting UCB INC drugs.

Summary for Ucb Inc
US Patents:15
Tradenames:26
Ingredients:21
NDAs:39
Drug Master File Entries: 1
Patent Litigation for Ucb Inc: See patent lawsuits for Ucb Inc

Drugs and US Patents for Ucb Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc KEMSTRO baclofen TABLET, ORALLY DISINTEGRATING;ORAL 021589-002 Oct 30, 2003 DISCN No No 6,024,981 ➤ Try a Free Trial Y ➤ Try a Free Trial
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-004 May 12, 2016 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-005 May 12, 2016 RX Yes Yes 6,911,461 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Ucb Inc ALBUTEROL SULFATE albuterol sulfate TABLET;ORAL 073121-001 Sep 29, 1992 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Ucb Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc TUSSIONEX PENNKINETIC chlorpheniramine polistirex; hydrocodone polistirex SUSPENSION, EXTENDED RELEASE;ORAL 019111-001 Dec 31, 1987 4,221,778 ➤ Try a Free Trial
Ucb Inc KEPPRA levetiracetam TABLET;ORAL 021035-003 Nov 30, 1999 4,837,223 ➤ Try a Free Trial
Ucb Inc UNIRETIC hydrochlorothiazide; moexipril hydrochloride TABLET;ORAL 020729-001 Jun 27, 1997 4,344,949 ➤ Try a Free Trial
Ucb Inc FLUXID famotidine TABLET, ORALLY DISINTEGRATING;ORAL 021712-002 Sep 24, 2004 6,024,981 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for UCB INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Transdermal Film 1 mg/24 hr, 2 mg/24 hr, 3 mg/24 hr,4 mg/24 hr,6 mg/24 hr, and 8 mg/24 hr ➤ Subscribe 2013-11-26
➤ Subscribe Oral Solution 10 mg/mL ➤ Subscribe 2012-10-29
➤ Subscribe Injection 10 mg/mL, 20 mL ➤ Subscribe 2016-06-30
➤ Subscribe Orally Disintegrating Tablets 0.25 mg, 0.5 mg, 1 mg and 2 mg ➤ Subscribe 2005-12-27
➤ Subscribe Tablets 1000 mg ➤ Subscribe 2007-01-24
➤ Subscribe Tablets 50 mg, 100 mg, 150 mg, and 200 mg ➤ Subscribe 2012-10-29
➤ Subscribe Extended-release Tablets 1000 mg ➤ Subscribe 2011-01-07
➤ Subscribe Tablets 7.5mg/12.5mg 15 mg/25 mg and 15 mg/12.5 mg ➤ Subscribe 2004-01-15

Non-Orange Book US Patents for Ucb Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,713,635 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Try a Free Trial
7,217,826 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Try a Free Trial
6,969,770 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses ➤ Try a Free Trial
6,048,899 Anticonvulsant enantiomeric amino acid derivatives ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Ucb Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
/2006 Austria ➤ Try a Free Trial PRODUCT NAME: ROTIGOTINE; REGISTRATION NO/DATE: EU/1/05/331/001 - EU/1/05/331/013 20060215
C0025 France ➤ Try a Free Trial PRODUCT NAME: ROTIGOTINE; REGISTRATION NO/DATE: EU/1/05/331/001 20060215
2006 00020 Denmark ➤ Try a Free Trial PRODUCT NAME: ROTIGOTINE
24/2006 Austria ➤ Try a Free Trial PRODUCT NAME: ROTIGOTINE
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Chubb
Covington
Dow
AstraZeneca
US Army
Mallinckrodt
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.